How much cash does Immix Biopharma, Inc. generate?

Immix Biopharma, Inc. (IMMX) generated -$32.1M in operating cash flow over the trailing twelve months.

What is Immix Biopharma, Inc.'s free cash flow?

After $697.7K of capital expenditures, Immix Biopharma, Inc.'s free cash flow was -$32.8M over the trailing twelve months, down 144.6% year over year.

Where does Immix Biopharma, Inc.'s cash flow data come from?

Every line is extracted from Immix Biopharma, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Immix Biopharma, Inc. IMMX Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$34.94M-18.9%	-$29.4M-24.8%	-$23.56M-1.9%	-$23.13M-10.6%	-$20.91M+3.6%
Depreciation and amortization	$299.17K+21.7%	$245.75K+14.7%	$214.24K+74.6%	$122.7K+80.2%	$68.08K+107%
Stock-based compensation	$2.15M-12.0%	$2.44M-5.2%	$2.58M-9.3%	$2.84M-3.6%	$2.95M-2.5%
Gain (loss) on sale of assets	——	——	——	——	——
Change in accrued liabilities	——	——	$4.1M-19.1%	$5.06M—	——
Change in other assets	——	——	——	——	-$715.14K-28.9%
Change in income taxes payable/receivable	-$55.2K+97.3%	-$2.06M-13.0%	-$1.82M—	——	——
Change in operating lease liabilities	-$117.41K-19.8%	-$98.01K—	——	——	——
Net cash from operating activities	-$32.07M-34.0%	-$23.93M-66.4%	-$14.38M-14.9%	-$12.51M-0.4%	-$12.45M+14.7%
Capital expenditures	$697.7K-4.8%	$732.93K-31.8%	$1.07M+10.4%	$974.04K+3.2%	$943.48K-19.9%
Purchases of investments	$12.63M+94.9%	$6.48M—	——	——	——
Proceeds from maturities/sales of investments	——	——	——	——	——
Net cash from investing activities	-$11.95M-65.6%	-$7.21M-571%	-$1.07M-10.4%	-$974.04K-3.2%	-$943.48K+19.9%
Proceeds from issuance of common stock	——	——	——	——	——
Payment of debt issuance costs	$173.84K+26.9%	$137K—	——	——	——
Net cash from financing activities	——	——	——	——	——
Effect of exchange rate changes on cash	——	——	——	$33.97K—	——
Net increase (decrease) in cash	$63.33M-16.9%	$76.25M—	——	——	——
Income taxes paid	——	——	——	——	——
Depreciation	$299.17K+21.7%	$245.75K+14.7%	$214.24K+74.6%	$122.7K+80.2%	$68.08K+107%
Increase (Decrease) in Income Taxes Receivable	-$55.2K+97.3%	-$2.06M-13.0%	-$1.82M—	——	——
Operating lease liabilities	-$117.41K-19.8%	-$98.01K—	——	——	——
Other current liabilities	——	——	$4.1M-19.1%	$5.06M—	——
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	——	-$715.14K-28.9%
Payments to Acquire Short-Term Investments	$12.63M+94.9%	$6.48M—	——	——	——
Proceeds From Sale Of Short Term Investments	——	——	——	——	——
Proceeds From Stock Warrants Exercised	——	$124.8K—	——	——	——
Gross realized gains	——	——	——	——	——
Finance Lease Right Of Use Asset Amortization	$136.92K+15.3%	$118.75K+17.6%	$100.97K+20.8%	$83.56K+1.1%	$82.63K+0.2%
Increase Decrease In Operating Lease Liability	-$117.41K-19.8%	-$98.01K—	——	——	——
Exercise Of Cashless Warrants	——	——	——	——	——
Income Taxes Paid, Net	——	——	——	——	——
Purchases Of Property And Equipment Included In Accounts Payable And Accrued Liabilities	——	——	——	——	——
Shares Issues For Vested Restricted Stock Awards	——	——	——	——	——
Free cash flow	-$32.77M-32.9%	-$24.66M-59.6%	-$15.45M-14.6%	-$13.48M-0.6%	-$13.4M+15.1%
Free cash flow	-$32.77M-32.9%	-$24.66M-59.6%	-$15.45M-14.6%	-$13.48M-0.6%	-$13.4M+15.1%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Immix Biopharma, Inc. generate?: Immix Biopharma, Inc. (IMMX) generated -$32.1M in operating cash flow over the trailing twelve months.
What is Immix Biopharma, Inc.'s free cash flow?: After $697.7K of capital expenditures, Immix Biopharma, Inc.'s free cash flow was -$32.8M over the trailing twelve months, down 144.6% year over year.
Where does Immix Biopharma, Inc.'s cash flow data come from?: Every line is extracted from Immix Biopharma, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.